Autoantibodies against GLP-1 and GIP hormones are elevated in diabetic patients and predict worse outcomes | Research

The takeaway

First study measuring autoantibodies against incretins: both GIP and GLP-1 antibody titers were significantly higher in 274 diabetic patients vs 109 controls, with GIP antibody positivity predicting significantly worse 5-year prognosis (p=0.0072).

First incretin autoantibodies found
Autoantibodies against GIP and GLP-1 are significantly elevated in diabetes and predict worse long-term prognosis—a completely new dimension of diabetes pathophysiology

What the researchers found

First incretin autoantibody study. GIP and GLP-1 antibodies: both significantly elevated in diabetes (p<0.01). GIP antibody positive: significantly worse 5-year prognosis (p=0.0072). GLP-1 antibody positive: trend toward worse prognosis (p=0.06). 274 patients, 109 controls, 4.9-year follow-up.

Why it matters

If incretin autoantibodies neutralize GIP and GLP-1, they could explain why some diabetic patients respond poorly to incretin-based therapies. This opens a completely new dimension of diabetes pathophysiology.

How the study worked

Retrospective cohort. 274 diabetic patients + 109 healthy controls. Incretin antibody titers by ALISA (amplified luminescent proximity homogeneous assay). Mean 4.9-year follow-up (max 10 years).

What this study cannot tell us

Retrospective. First study—needs replication. Antibody assay methodology novel. Cannot determine if antibodies cause or result from diabetes. Prognosis definition not specified.

How to read the evidence

First-of-its-kind retrospective cohort with novel autoantibody detection. Groundbreaking but needs independent validation.

When this study was published

Published in 2025.

The bigger picture

This is a paradigm-shifting discovery: diabetes may involve autoimmune destruction of incretin signaling, not just beta-cell destruction (T1D) or insulin resistance (T2D). Incretin autoantibodies could become both biomarkers and therapeutic targets.

Questions still open

Do incretin autoantibodies predict GLP-1 drug response?
Could removing incretin antibodies improve diabetes outcomes?
Is incretin autoimmunity a new diabetes subtype?

Common questions

Can your immune system attack your own gut hormones?

This study provides the first evidence that yes—diabetic patients have significantly higher levels of antibodies against GIP and GLP-1, the incretin hormones that help control blood sugar after eating. If these antibodies neutralize incretins, they could be a previously unknown cause of diabetes.

Could this explain why some diabetes treatments work poorly?

Potentially. If a patient has antibodies that neutralize GLP-1, GLP-1-based drugs (semaglutide, etc.) might be less effective. Testing for these antibodies could help predict which patients will respond best to incretin-based therapies and guide treatment selection.

Read the original research

Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes.

Scientific reports, 15(1), 38313

View on PubMed ↗Publisher’s paper ↗

Citation

Takemoto, Minoru; Zhang, Bo-Shi; Hayashi, Aiko; Yamagata, Hiroki; Yoshida, Yoich; Koshizaka, Masaya; Onishi, Shunichiro; Yamaga, Masaya; Yoshida, Tomohiko; Hashimoto, Takahide; Ohtake, Naoki; Ishikawa, Takahiro; Takizawa, Hirotaka; Hiwasa, Takaki. (2025). Increased autoantibodies against incretin indicate poor prognosis in patients with diabetes.. Scientific reports, 15(1), 38313. https://doi.org/10.1038/s41598-025-22337-z